Literature DB >> 20418644

Mycobacterium tuberculosis drug-resistance in previously treated patients in Ouagadougou, Burkina Faso.

L Sangare1, S Diande, S Kouanda, B I Dingtoumda, A Mourfou, F Ouedraogo, I Sawadogo, B Nebie, A Gueye, L T Sawadogo, A S Traore.   

Abstract

BACKGROUND: Tuberculosis drug-resistance becomes common in sub-Saharan Africa; however, very few data are available in Burkina Faso. The aim of this study is to assess the acquired resistance of Mycobacterium tuberculosis complex strains identified in TB patients to four first-line drugs in Ouagadougou.
METHODS: One hundred and ten (110) pulmonary tuberculosis patients with acid-fast bacilli-positive sputum and in situation of failure, relapse, or treatment abandonment were included in the study. Ninety six strains, including 92 (95.8%) M. tuberculosis and 4 (4.2%) M. africanum, were isolated from the sputum samples of these patients. Their drug susceptibility testing was performed using the proportion method. The first-line drugs tested were isoniazid (INH), streptomycin (STR), ethambutol (EMB), and rifampicin (RIF).
RESULTS: The overall drug-resistance rate of M. tuberculosis was 67.4% (n=60), including 3.4% to one drug, 18% to two, 10.1% to three, and 35.9% to four drugs. The resistance to INH, RIF, EMB, and STR were 67.4%, 51.7%, 50.6%, and 44.9%, respectively. Two strains of M. africanum were resistant to all drugs. Forty-six (51.7%) strains were multidrug-resistant (resistant to at least INH and RIF).
CONCLUSIONS: In previously treated patients, the level of resistance of M. tuberculosis complex to commonly used anti-tuberculosis drugs is very high in Ouagadougou. Our results showed that multidrug-resistant tuberculosis could be a public health problem in Burkina Faso.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20418644     DOI: 10.4103/1596-3519.62619

Source DB:  PubMed          Journal:  Ann Afr Med        ISSN: 0975-5764


  6 in total

1.  Mutations in the embC-embA intergenic region contribute to Mycobacterium tuberculosis resistance to ethambutol.

Authors:  Zhenling Cui; Yuanyuan Li; Song Cheng; Hua Yang; Junmei Lu; Zhongyi Hu; Baoxue Ge
Journal:  Antimicrob Agents Chemother       Date:  2014-09-02       Impact factor: 5.191

2.  Rise in rifampicin-monoresistant tuberculosis in Western Cape, South Africa.

Authors:  F K Mukinda; D Theron; G D van der Spuy; K R Jacobson; M Roscher; E M Streicher; A Musekiwa; G J Coetzee; T C Victor; B J Marais; J B Nachega; R M Warren; H S Schaaf
Journal:  Int J Tuberc Lung Dis       Date:  2012-02       Impact factor: 2.373

Review 3.  Diagnostic accuracy of a molecular drug susceptibility testing method for the antituberculosis drug ethambutol: a systematic review and meta-analysis.

Authors:  Song Cheng; Zhenling Cui; Yuanyuan Li; Zhongyi Hu
Journal:  J Clin Microbiol       Date:  2014-06-04       Impact factor: 5.948

4.  Strong decrease in streptomycin-resistance and absence of XDR 12 years after the Reorganization of the National Tuberculosis Control Program in the Central Region of Cameroon.

Authors:  Larissa Kamgue Sidze; Emmanuel Mouafo Tekwu; Christopher Kuaban; Jean-Paul Assam Assam; Jean-Claude Tedom; Sara Eyangoh; François-Xavier Fouda; Désiré Nolna; Francine Ntoumi; Matthias Frank; Véronique N Penlap Beng
Journal:  PLoS One       Date:  2014-06-05       Impact factor: 3.240

5.  The emerging threat of pre-extensively drug-resistant tuberculosis in West Africa: preparing for large-scale tuberculosis research and drug resistance surveillance.

Authors:  Florian Gehre; Jacob Otu; Lindsay Kendall; Audrey Forson; Awewura Kwara; Samuel Kudzawu; Aderemi O Kehinde; Oludele Adebiyi; Kayode Salako; Ignatius Baldeh; Aisha Jallow; Mamadou Jallow; Anoumou Dagnra; Kodjo Dissé; Essosimna A Kadanga; Emmanuel Oni Idigbe; Catherine Onubogu; Nneka Onyejepu; Aissatou Gaye-Diallo; Awa Ba-Diallo; Paulo Rabna; Morto Mane; Moumine Sanogo; Bassirou Diarra; Zingue Dezemon; Adama Sanou; Madikay Senghore; Brenda A Kwambana-Adams; Edward Demba; Tutty Faal-Jawara; Samrat Kumar; Leopold D Tientcheu; Adama Jallow; Samba Ceesay; Ifedayo Adetifa; Assan Jaye; Mark J Pallen; Umberto D'Alessandro; Beate Kampmann; Richard A Adegbola; Souleymane Mboup; Tumani Corrah; Bouke C de Jong; Martin Antonio
Journal:  BMC Med       Date:  2016-11-03       Impact factor: 8.775

6.  Risk factors for tuberculosis treatment failure among pulmonary tuberculosis patients in four health regions of Burkina Faso, 2009: case control study.

Authors:  Bernard Sawadogo; Khin San Tint; Mufuta Tshimanga; Lazarus Kuonza; Laurent Ouedraogo
Journal:  Pan Afr Med J       Date:  2015-06-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.